eligibility_summary
Eligibility: Adults (≥18) with untreated, CD20+ follicular lymphoma grade 1–3A (2016 WHO), requiring therapy, high-risk by FLIPI2, measurable disease on CT/PET-CT, suitable for ZGR, and consented. Exclude: transformed or grade 3B FL, active HBV/HCV or HIV, contraindications to study drugs, pregnancy/lactation, or investigator-judged unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in high-risk, treatment-naive follicular lymphoma testing ZGR: zanubrutinib + obinutuzumab + lenalidomide. Zanubrutinib: oral covalent BTK inhibitor (small molecule) that blocks B‑cell receptor signaling to reduce malignant B‑cell survival/proliferation. Obinutuzumab: type II, glycoengineered anti‑CD20 monoclonal antibody that depletes CD20+ B cells via enhanced ADCC/ADCP and direct cell death. Lenalidomide: oral IMiD that binds cereblon, triggers IKZF1/3 degradation, boosts T/NK-cell activity, and has anti-angiogenic effects. Targets: CD20+ FL B cells, BCR/BTK pathway, cereblon‑mediated immune activation.